Persistent subretinal fluid, or SRF, in the course of anti-VEGF treatment may operate as a compensatory mechanism that maintains the function of the degenerating macula and prevents progression to atrophy, according to one presenter at the virtual Association for Research in Vision and Ophthalmology meeting.
“Clinical trial experience suggests that the best vision outcomes in neovascular AMD are observed when steady state induced by anti-VEGF treatment includes some residual, treatment-resistant SRF. Using the HARBOR clinical trial data, we investigated the effect of SRF thickness on
Uncategorized